← 返回

检查肿瘤和免疫治疗中 CD24 检查点的功能

英文原题:Checkpoint CD24 function on tumor and immunotherapy.

查看英文原题

Checkpoint CD24 function on tumor and immunotherapy.

PubMed 2024/02/29(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

CD24是一种存在于细胞表面的蛋白,在癌细胞的增殖、侵袭和扩散中起着至关重要的作用。它通过糖基磷脂酰肌醇(GPI)附着在细胞膜上,并与癌症患者的预后和生存率相关。CD24与免疫细胞(如NK 细胞和巨噬细胞)上存在的抑制性受体Siglec-10相互作用,导致NK 细胞细胞毒性和巨噬细胞介导的吞噬作用受到抑制。这种相互作用帮助肿瘤细胞逃避免疫检测和攻击。尽管将CD24用作癌症免疫治疗的免疫检查点受体靶点仍处于早期阶段,但临床试验已显示出有希望的结果。靶向CD24的单克隆抗体已被发现耐受性良好且安全。其他临床前研究正在探索使用嵌合抗原受体(CAR)T细胞、抗体-药物偶联物和基因治疗来靶向CD24并增强针对肿瘤的免疫反应。总之,本综述聚焦于CD24在免疫系统中的作用,并为CD24作为癌症免疫治疗中有前景的免疫检查点提供证据。

展开英文摘要原文

CD24 is a protein found on the surface of cells that plays a crucial role in the proliferation, invasion, and spread of cancer cells. It adheres to cell membranes through glycosylphosphatidylinositol (GPI) and is associated with the prognosis and survival rate of cancer patients. CD24 interacts with the inhibitory receptor Siglec-10 that is present on immune cells like natural killer cells and macrophages, leading to the inhibition of natural killer cell cytotoxicity and macrophage-mediated phagocytosis. This interaction helps tumor cells escape immune detection and attack.

Although the use of CD24 as a immune checkpoint receptor target for cancer immunotherapy is still in its early stages, clinical trials have shown promising results. Monoclonal antibodies targeting CD24 have been found to be well-tolerated and safe.

Other preclinical studies are exploring the use of chimeric antigen receptor (CAR) T cells, antibody-drug conjugates, and gene therapy to target CD24 and enhance the immune response against tumors. In summary, this review focuses on the role of CD24 in the immune system and provides evidence for CD24 as a promising immune checkpoint for cancer immunotherapy.

论文信息

作者
Huang S、Zhang X、Wei Y、Xiao Y
单位
Department of Radiology, First Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China.China
文献类型
综述
期刊
Frontiers in immunology2024
原文标识
PubMed 38487533 · DOI 10.3389/fimmu.2024.1367959